v3.25.2
Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Income Statement [Abstract]        
Research and development expenses $ 4,926,936 $ 2,823,064 $ 9,508,608 $ 6,412,077
General and administrative expenses 4,949,020 795,660 7,384,371 1,812,401
Operating Loss (9,875,956) (3,618,724) (16,892,979) (8,224,478)
Other (Expense) Income:        
Grant income 322,655   575,209  
Interest expense   (1,357,458)   (1,612,580)
Interest income 29,466 58,040 129,564 64,682
Change in fair value of derivative liability   (347,093)   (335,001)
Total Other (Expense) Income 352,121 (1,646,511) 704,773 (1,882,899)
Net Loss (9,523,835) (5,265,235) (16,188,206) (10,107,377)
Series A Preferred cash dividend (2,089)   (4,178)  
Net Loss attributable to common stockholders $ (9,525,924) $ (5,265,235) $ (16,192,384) $ (10,107,377)
Net Loss per share, basic $ (0.21) $ (0.43) $ (0.36) $ (0.83)
Net Loss per share, diluted $ (0.21) $ (0.43) $ (0.36) $ (0.83)
Weighted-average shares outstanding, basic 44,555,095 12,178,522 44,983,198 12,176,127
Weighted-average shares outstanding, diluted 44,555,095 12,178,522 44,983,198 12,176,127

Source